Resistentia Pharmaceuticals receives regulatory approval to begin phase I clinical trial of its novel universal allergy immunotherapy

Resistentia Pharmaceuticals announced today that its Clinical trial application for a phase I trial of its universal allergy immunotherapeutic RP01 has been approved by the Swedish Medical Products Agency. The application was submitted on December 1st 2005 and its clearance will enable the Company to commence clinical investigations during March 2006. ”This approval represents our most important milestone so far in the development of our anti-IgE immunotherapeutic for the treatment of allergic disease” says Mr. Marcus Bosson, Chief Executive Officer of Resistentia. The phase I trial will be performed in healthy volunteers and will primarily investigate the safety and tolerability of the product. In addition, the trial will also provide indicative information on efficacy and dose requirements. "There still remains a large unmet medical need in patients with allergic asthma, and this innovative therapy represents a very promising alternative for many patients who are currently inadequately treated" says Dr. Lars Larsson, Chief Medical Officer. For more information, contact Chief Executive Officer Marcus Bosson, phone +46-706938281, marcus.bosson@resistentia.se Resistentia Pharmaceuticals AB Visiting address: Kungsängsvägen 25 Box 853, SE-751 08 Uppsala Sweden Tel: +46 (0)18 65 39 00 Fax: +46 (0)18 65 39 10 Internet: www.resistentia.se VATno. SE556554158701